Breaking: Federal Law Doesn’t Preempt Arkansas’s Novel 340B Contract Pharmacy Law, Judge Rules

Arkansas Insurance Department office sign
The Arkansas Insurance Department will imminently enforce a state 340B contract pharmacy law following a key federal appeals court decision.

A federal district judge ruled yesterday that Arkansas’s novel 340B anti-discrimination law is not preempted by the 340B statute nor by the U.S. Food and Drug Administration’s Risk Evaluation and Mitigation Strategies requirements.

U.S. Senior District Judge Billy Roy Wilson’s

Read More »

Michigan Senate Rejects Attempt to Weaken Recent 340B Anti-Discrimination Law

Michigan Senate chamber
A bill that would enact contract pharmacy protections in Michigan has garnered renewed attention from 340B supporters and critics, alike, in the final days before the state’s legislature is set to recess for the summer.

The Michigan Senate has defeated legislation that hospitals say would have removed language from a nearly year-old state law that stops payers, pharmacy benefit managers, or other third parties from requiring 340B claims modifiers except as required to prevent Medicaid

Read More »

340B’s Critics Often Misunderstand its Intent, Ex-House E&C Chair Waxman Says in Health Affairs Commentary

Henry Waxman headshot
Ex-U.S. Rep. Henry Waxman (D-Calif.) says in a Health Affairs commentary that criticism of the drug discount program often “reflect[s] a misunderstanding of Congress’ intent.”

Henry Waxman, a California Democrat who was one of the original sponsors of the 340B law when it was created in 1992, says in a commentary in Health Affairs that criticism of the drug discount program often “reflect[s] a misunderstanding

Read More »

340B Report Publisher and CEO Slafsky: Expect More Attention to 340B in New Congress

U.S. Capitol building East elevation
Be prepared for a lot more attention on the 340B program in the upcoming Congress, 340B Report Publisher and CEO Ted Slafsky predicts.

Be prepared for a lot more attention on the 340B program in the upcoming Congress, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.

340B was a hot topic in Congress

Read More »

Novo Nordisk Announces Third Round of 340B Refunds This Year

Novo Nordisk wordmark on building facade
Novo Nordisk for the third time this year has announced refunds for 340B overcharges due to revisions of Medicaid pricing data.

Drug manufacturer Novo Nordisk for the third time this year has announced refunds for 340B overcharges due to revisions of Medicaid pricing data.

The U.S. Health Resources and Services Administration posted the company’s notice to covered entities on its website

Read More »

Senior U.S. House Democrat and Republican Say They’re Hopeful Congress Will Act on 340B; Hearings Expected in New Congress

Rep. Robin Kelly (D-IL) and Rep. Brett Guthrie (R-KY) headshots
U.S. Reps. Robin Kelly (D-Ill.) and Brett Guthrie (R-Ky.) each said during an event yesterday they were hopeful Congress would act on 340B—Kelly regarding covered entities' concerns and Guthrie regarding those of payers and manufacturers.

The Democratic vice chair of the U.S. House Energy & Commerce Committee said during a media event yesterday she hopes Congress will address healthcare providers’ concerns about the 340B program during its lame duck session scheduled to end Dec. 15.

Read More »

Lilly for the Fifth Time This Year Announces Refunds for 340B Overcharges

Lilly corporate center signage
Lilly for the fifth time this year has announced refunds for overcharges on 340B-acquired drugs.

Drug manufacturer Eli Lilly for the fifth time this year has announced refunds for overcharges on 340B-acquired drugs. The latest round is for purchases during the first quarter of 2020.

The U.S. Health Resources and Services Administration posted Lilly’s

Read More »

Novo Nordisk Updates 340B Contract Pharmacy Policy, Will Allow Claims Submission to 340B ESP

Novo Nordisk signage and building
Novo Nordisk has decided to let 340B hospitals buy its drugs at a reduced 340B price for shipment to an unlimited number of contract pharmacies if the hospitals submit their claims data to 340B ESP.

Novo Nordisk on Jan.1 will implement a policy to let 340B hospitals buy its drugs at a reduced 340B price for shipment to an unlimited number of contract pharmacies if the hospitals submit their claims data for such drugs to

Read More »

RWC-340B Assessing Dispute Resolution Proposed Rule’s Impact on Its Lawsuit and Current Dispute Resolution Petition

Ryan White Clinics-340B wordmark
RWC-340B is assessing how HRSA's proposed new 340B dispute resolution process would affect the group's ongoing dispute with AstraZeneca and ongoing lawsuit against HRSA and HHS.

Ryan White Clinics for 340B Access told a federal district judge last week it needs time to assess how proposed new 340B administrative dispute resolution regulations, if finalized, could affect the 340B overcharging claims it brought against AstraZeneca under the

Read More »

Mike Braun, Key U.S. Senator on 340B Matters, Won’t See Re-Election in 2024

Sen. Mike Braun (R-IN) headshot
U.S. Sen. Mike Braun (R-Ind.), a key voice on 340B matters, is running for governor of Indiana in 2024 instead of seeking re-election to Congress.

U.S. Sen. Mike Braun (R-Ind.), whom 340B covered entities have considered both a friend and foe, has decided to run for governor of Indiana in 2024 rather than seek reelection to the Senate.

A senator since 2019, Braun serves on

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live